Navigation Links
Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
Date:9/14/2010

WORCESTER, Mass., Sept. 14 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT; www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has entered into an exclusive Product Licensing & Distribution Agreement with PMG S.A. (www.pmgpharma.com) for the registration, marketing, distribution and sale of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, in Chile.

PMG PHARMA is a Chilean pharmaceutical corporation located in Santiago and focused in three therapeutic areas: diabetes, nephrology and an injectable product line sold in hospitals and pharmacies.  PMG PHARMA represents fifteen international companies, all related to its core business in diabetes.  PMG PHARMA's principals include the managing board comprised of a General Manager, a Marketing Manager, and a Sales Manager, each of whom have extensive experience in the diabetes space.  Some of their achievements include successfully introducing the blood glucose monitoring system from Boheringer Manheim (now known as Roche) in Chile as well as introducing Novo Nordisk's  monocomponent insulin and human recombinant insulin (including the NovoPen®) in Chile. This long history will in the diabetes segment will provide a solid platform for Generex Oral-lyn's™ market introduction in Chile.    

Chile has a population of over 16.8 million and a diabetes prevalence of 7.2% (per the International Diabetes Federation).  Patients under insulin therapy are estimated to be approximately 85,000.

"We are delighted to have licensed Generex Oral-lyn™ to PMG PHARMA, a well-established company whose principals have a long history in marketing diabetes products," said Anna Gluskin, Generex's President and Chief Executive Officer.  "This alliance is important as it opens up another key country in South America where diabetes is a highly prevalent condition."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
3. RSB Spine, LLC, Announces Additional FDA Clearance for the InterPlate® L-Ti
4. Elbit Imaging Announces Share Purchase Agreement With Enter Holdings
5. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
6. Shield Healthcare Announces 10th Annual Caregiver Story Contest
7. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
8. Genoptix Announces Participation at the 2010 UBS Global Life Sciences Conference
9. ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
10. Sysmex America Announces LabCorp Hematology Automation Agreement
11. K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , 22. März 2017   VWR ... weltweit tätige Anbieter von Produkten und Dienstleistungen ... Erwerb von EPL Archives Inc. bekannt, eines ... Kunden im kompletten Zyklus regulierter Forschung, Entwicklung ... Proben, Speicherung von Dokumenten und Zusatzdienstleistungen zur ...
(Date:3/22/2017)... March 22, 2017 TapImmune, Inc. ... in the development of innovative peptide and gene-based ... disease, today announced that it will participate in ... Dr. Glynn Wilson , Chairman and CEO ... company,s business, clinical pipeline and partnering opportunities for ...
(Date:3/22/2017)... March 22, 2017 A new independent ... is the proven ultraviolet-C (UV-C) disinfection solution of ... (HAIs). Published in the March ... Control , the peer-reviewed study of UV-C disinfection ... Vancouver General Hospital and Rochester General Hospital. According ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy and ... published author Bonetta Rose, a wife, mother and grandmother committed to sharing her many ... Publishing, Bonetta Rose‘s new book presents actual events in the life of her family, ...
(Date:3/23/2017)... , ... March 23, 2017 , ... “The Trainer”: ... of published author, Scotty, a fiction writer with an active imagination and an enthusiasm ... new book follows the tale of Wild Bill Hart, who sat looking at the ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had won the ... place at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that ... bypasses that. Healthcare facilities across the country are always forced to focus ... and hospitals, across the country, an efficient and quick way to estimate savings ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett Syndrome Research ... neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is caused by ... exclusively strikes females. Following a normal infancy, Rett Syndrome takes effect in ...
Breaking Medicine News(10 mins):